Trailhead Biosystems Launches iPSC-Derived Endothelial Cells to Expand Vascular Research Portfolio

New updates have been reported about Trailhead Biosystems Inc.

Trailhead Biosystems Inc. has introduced TrailBio Endothelial Cells, a commercially available, induced pluripotent stem cell–derived endothelial model designed to provide a consistent and scalable alternative to donor-derived primary cells. Built using the company’s proprietary High-Dimensional Design-of-Experiments platform, the product aims to reduce experimental variability and offer a standardized vascular model for research applications across drug discovery and toxicity testing.

The new cells exhibit over 90% purity and express key endothelial markers such as CD31, CD144, and von Willebrand Factor, and they have been functionally validated in angiogenic tube formation, VEGF-driven migration and invasion assays, inflammatory activation with TNF-α, and acetylated LDL uptake. Cryopreserved vials are supplied with one million ready-to-use cells that can be expanded for at least three passages without losing phenotype or function, positioning Trailhead to deepen its presence in vascular biology, inflammation studies, and translational research workflows. CEO David Llewellyn describes the launch as a significant expansion of the company’s iPSC-derived cell portfolio, while the scientific leadership highlights the blend of purity, functional performance, and scalability as a differentiator that could support broader adoption in preclinical research and strengthen Trailhead’s role in enabling reproducible human cell models for pharmaceutical and biotechnology customers.